Pliant Therapeutics to Participate in Upcoming Investor Events
Pliant Therapeutics, Inc. (PLRX)
Company Research
Source: GlobeNewswire
SOUTH SAN FRANCISCO, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today announced participation in the following May investor events. RBC Capital Markets Global Healthcare Conference Bernard Coulie, M.D., Ph.D., Pliant’s President and Chief Executive Officer, and Éric Lefebvre, M.D., Pliant’s Chief Medical Officer, will participate in a fireside chat on Tuesday, May 14, 2024, at 1:35 p.m. Eastern Time.Stifel West Coast Bus Tour Members of Pliant’s senior management team will meet with investors on Thursday, May 23, 2024, as part of an invitation-only event hosted by Stifel.Piper Sandler Virtual Lung Investor Day Keith Cummings, M.D., Pliant’s Chief Financial Officer, and Greg Cosgrove, M.D., Pliant’s Vice President, Clinical Development, will participate in a fireside chat on Thursday, May 23, 2024, as
Show less
Read more
Impact Snapshot
Event Time:
PLRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PLRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PLRX alerts
High impacting Pliant Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
PLRX
News
- Pliant Therapeutics, Inc. (NASDAQ: PLRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $36.00 price target on the stock.MarketBeat
- Pliant Therapeutics Announces Positive Topline Data from a Phase 2a Collagen PET Imaging Clinical Trial of Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis [Yahoo! Finance]Yahoo! Finance
- Pliant Therapeutics Announces Positive Topline Data from a Phase 2a Collagen PET Imaging Clinical Trial of Bexotegrast in Patients with Idiopathic Pulmonary FibrosisGlobeNewswire
- Pliant Therapeutics First Quarter 2024 Earnings: US$0.78 loss per share (vs US$0.67 loss in 1Q 2023) [Yahoo! Finance]Yahoo! Finance
- Pliant Therapeutics, Inc. (NASDAQ: PLRX) had its price target lowered by analysts at Citigroup Inc. from $45.00 to $44.00. They now have a "buy" rating on the stock.MarketBeat
PLRX
Earnings
- 11/9/23 - Beat
PLRX
Sec Filings
- 5/14/24 - Form 8-K
- 5/6/24 - Form 10-Q
- 5/6/24 - Form 8-K
- PLRX's page on the SEC website